

# Geum-Youn Gwak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5484144/publications.pdf>

Version: 2024-02-01

119  
papers

3,703  
citations

126907

33  
h-index

155660

55  
g-index

122  
all docs

122  
docs citations

122  
times ranked

5343  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 427-437.e5.	4.4	33
2	Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4565-4573.	2.3	11
3	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. <i>Genome Medicine</i> , 2022, 14, 1.	8.2	68
4	Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study. <i>BMC Medicine</i> , 2022, 20, 18.	5.5	6
5	Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. <i>Scientific Reports</i> , 2022, 12, 7647.	3.3	13
6	Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 1082-1087.	1.7	5
7	Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study. <i>Hepatology</i> , 2022, 76, 1746-1754.	7.3	24
8	Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2816-2825.	2.3	5
9	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12.	2.2	6
10	Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 274-280.	1.5	0
11	A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2021, 53, 210-215.	0.9	2
12	Survival in untreated hepatocellular carcinoma: A national cohort study. <i>PLoS ONE</i> , 2021, 16, e0246143.	2.5	8
13	Outcome of patients with severe alcoholic hepatitis after Model for End-Stage Liver Disease-based allocation system implementation in Korea. <i>Korean Journal of Transplantation</i> , 2021, 35, 24-32.	0.1	2
14	Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e529-e534.	1.6	14
15	Inclusive Quantification Assay of Serum Des <sup>3</sup> -Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry. <i>Hepatology Communications</i> , 2021, 5, 1767-1783.	4.3	4
16	The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nationwide Cohort Study. <i>Hepatology</i> , 2021, 74, 2988-2997.	7.3	10
17	Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1392-1399.	2.0	13
18	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>Hepatology International</i> , 2021, 15, 892-900.	4.2	15

#	ARTICLE	IF	CITATIONS
19	Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study. <i>PLoS ONE</i> , 2021, 16, e0255624.	2.5	1
20	Predictors and outcome of emergent Liver transplantation for patients with acute-on-chronic liver failure. <i>Digestive and Liver Disease</i> , 2021, 53, 1004-1010.	0.9	14
21	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00290.	2.5	9
22	Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. <i>Liver Cancer</i> , 2021, 10, 52-62.	7.7	30
23	Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. <i>Scandinavian Journal of Gastroenterology</i> , 2021, , 1-8.	1.5	3
24	Alcohol Intake and Mortality in Patients With Chronic Viral Hepatitis: A Nationwide Cohort Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 329-335.	0.4	14
25	Weight Change and Development of Subclinical Carotid Atherosclerosis Among Metabolically Healthy Adults: A Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e410-e416.	3.6	3
26	Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Hepatology</i> , 2020, 71, 2023-2032.	7.3	66
27	Nonalcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 833-839.	2.8	66
28	Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. <i>International Journal of Epidemiology</i> , 2020, 49, 1562-1571.	1.9	14
29	Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2020, 52, 881-888.	0.6	0
30	Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients. <i>Journal of Viral Hepatitis</i> , 2020, 27, 739-746.	2.0	8
31	Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 896-903.	2.0	26
32	Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients: Functional cure unlikely. <i>Journal of Viral Hepatitis</i> , 2020, 27, 951-954.	2.0	5
33	Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 516-528.	8.9	42
34	Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 65-78.	1.7	11
35	Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. <i>Annals of Surgical Treatment and Research</i> , 2020, 99, 238.	1.0	20
36	Comparison of Mac-2 Binding Protein Glycosylation Isomer, Fibroscan, and Other Fibrosis Markers for Assessing Liver Cirrhosis in Patients with Chronic Hepatitis B Virus-mediated Hepatocellular Carcinoma. <i>Laboratory Medicine Online</i> , 2020, 10, 109.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Clinical impact of healthcare-associated acquisition in cirrhotic patients with community-onset spontaneous bacterial peritonitis. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 215-221.	1.7	6
38	Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2028-2035.	2.8	17
39	Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?. <i>PLoS ONE</i> , 2019, 14, e0213547.	2.5	12
40	Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. <i>Journal of Hepatology</i> , 2019, 71, 35-44.	3.7	29
41	Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. <i>BMC Cancer</i> , 2019, 19, 286.	2.6	11
42	Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2019, 14, e0210730.	2.5	64
43	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 23-32.	4.2	62
44	Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study. <i>European Journal of Endocrinology</i> , 2019, 181, 185-192.	3.7	46
45	Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1062-1071.	2.3	23
46	Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. <i>Liver International</i> , 2018, 38, 1442-1448.	3.9	65
47	Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 727-733.	1.5	5
48	Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. <i>Scientific Reports</i> , 2018, 8, 4718.	3.3	68
49	Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors. <i>Annals of Surgery</i> , 2018, 268, 1043-1050.	4.2	18
50	Noninvasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia. <i>Liver International</i> , 2018, 38, 68-75.	3.9	42
51	Nonalcoholic fatty liver disease and the development of reflux esophagitis: A cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1053-1058.	2.8	12
52	Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1447-1452.	1.6	13
53	Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study. <i>Journal of Korean Medical Science</i> , 2018, 33, e264.	2.5	13
54	Percutaneous Radiofrequency Ablation of Small (1-2cm) Hepatocellular Carcinomas Inconspicuous on B-Mode Ultrasonographic Imaging: Usefulness of Combined Fusion Imaging with MRI and Contrast-Enhanced Ultrasonography. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 1-9.	1.9	16

#	ARTICLE	IF	CITATIONS
55	Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma. <i>Radiation Oncology Journal</i> , 2018, 36, 25-34.	1.5	16
56	Laparoscopic Liver Resection of Hepatocellular Carcinoma with a Tumor Size Larger Than 5 cm: Review of 45 Cases in a Tertiary Institution. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2017, 27, 799-803.	1.0	14
57	Letter: <i>Helicobacter pylori</i> -related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 577-578.	3.7	0
58	Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1100-1106.	2.8	23
59	Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. <i>Hepatology</i> , 2017, 66, 772-783.	7.3	37
60	Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. <i>Gut</i> , 2017, 66, 323-329.	12.1	125
61	Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. <i>Journal of Hepatology</i> , 2017, 67, 1274-1280.	3.7	120
62	Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3235-3242.	2.3	44
63	Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. <i>Hepatology</i> , 2017, 66, 335-343.	7.3	144
64	Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 345-353.	3.7	54
65	Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 636-646.	1.7	17
66	Nonlinear tumor evolution from dysplastic nodules to hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 2076-2082.	1.8	8
67	Metabolically-healthy obesity is associated with higher prevalence of colorectal adenoma. <i>PLoS ONE</i> , 2017, 12, e0179480.	2.5	14
68	Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trial. <i>Oncotarget</i> , 2017, 8, 52651-52664.	1.8	12
69	The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 42-50.	8.9	13
70	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. <i>Gut and Liver</i> , 2017, 11, 528-534.	2.9	22
71	Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2016, 10, 939-947.	2.9	15
72	Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 47794-47807.	1.8	24

#	ARTICLE	IF	CITATIONS
73	Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 3785.	3.3	15
74	Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis. <i>Medicine (United States)</i> , 2016, 95, e2578.	1.0	6
75	Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. <i>Gut</i> , 2016, 65, 1721-1732.	12.1	31
76	Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3354-3362.	2.3	13
77	The recommended treatment algorithms of the <scp>BCLC</scp> and <scp>HKLC</scp> staging systems: does following these always improve survival rates for <scp>HCC</scp> patients?. <i>Liver International</i> , 2016, 36, 1490-1497.	3.9	51
78	Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis. <i>Gastroenterology</i> , 2016, 151, 481-488.e1.	1.3	95
79	Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma. <i>European Radiology</i> , 2016, 26, 3437-3446.	4.5	24
80	The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. <i>Journal of Clinical Lipidology</i> , 2016, 10, 289-298.	1.5	47
81	Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial. <i>International Journal of Hyperthermia</i> , 2016, 32, 331-338.	2.5	6
82	Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. <i>PLoS ONE</i> , 2016, 11, e0154986.	2.5	48
83	Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 250-258.	8.9	42
84	Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 477-486.	8.9	23
85	Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2016, 10, 295.	2.9	14
86	Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. <i>Gut and Liver</i> , 2016, 10, 796-802.	2.9	14
87	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. <i>Liver International</i> , 2015, 35, 2363-2369.	3.9	21
88	Hepatocellular carcinoma risk in chronic hepatitis B virusâ€“infected compensated cirrhosis patients with low viral load. <i>Hepatology</i> , 2015, 62, 694-701.	7.3	106
89	Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. <i>Journal of Korean Medical Science</i> , 2015, 30, 1618.	2.5	12
90	Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the Extent of Portal Vein Invasion and the Type of Extrahepatic Spread. <i>PLoS ONE</i> , 2015, 10, e0124434.	2.5	43

#	ARTICLE	IF	CITATIONS
91	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 1383-1391.e6.	1.3	371
92	Aggressive Intrahepatic Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance. <i>Radiology</i> , 2015, 276, 274-285.	7.3	113
93	Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3794-3800.	2.3	1
94	Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors. <i>Journal of Hepatology</i> , 2015, 62, 1112-1121.	3.7	50
95	Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. <i>PLoS ONE</i> , 2015, 10, e0144777.	2.5	5
96	Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 232.	8.9	7
97	Intrahepatic bile duct adenoma in a patient with chronic hepatitis B accompanied by elevation of alpha-fetoprotein. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 393.	8.9	4
98	Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 32.	1.7	19
99	Relationship of Liver Stiffness and Controlled Attenuation Parameter Measured by Transient Elastography with Diabetes Mellitus in Patients with Chronic Liver Disease. <i>Journal of Korean Medical Science</i> , 2014, 29, 1113.	2.5	4
100	The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 283.	8.9	12
101	Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease. <i>Atherosclerosis</i> , 2014, 234, 270-275.	0.8	29
102	High-Mobility Group Box 1 Is Dispensable for Autophagy, Mitochondrial Quality Control, and Organ Function In Vivo. <i>Cell Metabolism</i> , 2014, 19, 539-547.	16.2	82
103	The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 795-801.	3.9	51
104	Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. <i>Gut</i> , 2014, 63, 1943-1950.	12.1	149
105	Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort. <i>PLoS ONE</i> , 2014, 9, e112184.	2.5	49
106	Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma. <i>Radiation Oncology Journal</i> , 2014, 32, 14.	1.5	28
107	Clinical Features, Image Findings, and Prognosis of Inflammatory Pseudotumor of the Liver: A Multicenter Experience of 45 Cases. <i>Gut and Liver</i> , 2014, 8, 58-63.	2.9	64
108	Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. <i>Hepatology International</i> , 2013, 7, 1010-1018.	4.2	11

#	ARTICLE	IF	CITATIONS
109	A comparison of clevudine and entecavir for treatment-naïve patients with chronic hepatitis B: results after 2 years of treatment. <i>Hepatology International</i> , 2013, 7, 106-110.	4.2	4
110	Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels. <i>World Journal of Gastroenterology</i> , 2013, 19, 2256.	3.3	3
111	Ultrasonographically Detected Non-Alcoholic Fatty Liver Disease Is an Independent Predictor for Identifying Patients With Insulin Resistance in Non-Obese, Non-Diabetic Middle-Aged Asian Adults. <i>American Journal of Gastroenterology</i> , 2012, 107, 561-567.	0.4	104
112	Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease. <i>Liver International</i> , 2012, 32, 937-944.	3.9	29
113	Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway. <i>World Journal of Gastroenterology</i> , 2012, 18, 679.	3.3	47
114	Clinical Impact of the Development of YMDD Mutants in Hepatitis B Virus-Associated Glomerulonephritis. <i>Hepato-Gastroenterology</i> , 2011, 58, 1291-1295.	0.5	5
115	The correlation of hepatitis B virus pre-S mutation with mitochondrial D-loop mutations and common deletions in hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , 2011, 58, 522-8.	0.5	5
116	Disease progression and the risk factor analysis for chronic hepatitis C. <i>Liver International</i> , 2008, 28, 1363-1369.	3.9	35
117	Occult hepatitis B virus infection in chronic hemodialysis patients in Korea. <i>Hepato-Gastroenterology</i> , 2008, 55, 1721-4.	0.5	10
118	The correlation of hepatitis B virus pre-S mutation with cellular oxidative DNA damage in hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , 2008, 55, 2028-32.	0.5	4
119	Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development. <i>Scandinavian Journal of Gastroenterology</i> , 0, , 1-8.	1.5	0